AMG 355
Alternative Names: AMG-355Latest Information Update: 20 Mar 2024
At a glance
- Originator Amgen
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CCR8 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 07 Mar 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06131398)
- 07 Mar 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06131398)
- 15 Feb 2024 Phase-I clinical trials in Solid tumours (Late-stage disease) (IV) before February 2024 (Amgen pipeline, February 2024 )